US 11,931,536 B2
Surface liquefied drug-coated balloon
Yulin Weng, Suzhou (CN); Quan Shi, Suzhou (CN); Baorui Liu, Suzhou (CN); and Zhuoyang Gu, Suzhou (CN)
Assigned to DK Medical Technology Co., Ltd., Sozhou (CN)
Appl. No. 16/634,031
Filed by DK Medical Technology Co., Ltd., Suzhou (CN)
PCT Filed Jul. 26, 2017, PCT No. PCT/CN2017/094445
§ 371(c)(1), (2) Date Jan. 24, 2020,
PCT Pub. No. WO2019/019043, PCT Pub. Date Jan. 31, 2019.
Prior Publication US 2020/0197673 A1, Jun. 25, 2020
Int. Cl. A61M 31/00 (2006.01); A61F 2/82 (2013.01); A61K 31/20 (2006.01); A61K 31/337 (2006.01); A61K 47/14 (2017.01); A61L 29/16 (2006.01); A61L 31/16 (2006.01); A61M 25/10 (2013.01)
CPC A61M 25/1029 (2013.01) [A61K 31/337 (2013.01); A61K 47/14 (2013.01); A61M 25/104 (2013.01); A61M 2025/1004 (2013.01); A61M 2025/1031 (2013.01); A61M 2025/105 (2013.01)] 5 Claims
OG exemplary drawing
 
1. A drug-coated balloon comprising a surface liquefied drug coating and a balloon, wherein the drug coating consists of a lipophilic excipient and a drug, the drug accounts for 20% to 50% of the total weight of the drug coating, the lipophilic excipient accounts for 50% to 80% of the total weight of the drug coating, and the lipophilic excipient is a triglyceride.